Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

por Small, E J, Higano, C S, Kantoff, P W, Whitmore, J B, Frohlich, M W, Petrylak, D P
Publicado 2014

Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry

por Kwon, D.H., Vashisht, R., Borno, H.T., Aggarwal, R.R., Small, E.J., Butte, A.J., Huang, F.W.
Publicado 2021

1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium

por Hong, J., Borno, H.T., Harismendy, O., Yousefi, S., Cinar, P., Rugo, H.S., Kim, M-O., Koshkin, V.S., Bailey, A., McKay, R.R., Small, E.J.
Publicado 2021

Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer

por Small, E J, Saad, F, Chowdhury, S, Oudard, S, Hadaschik, B A, Graff, J N, Olmos, D, Mainwaring, P N, Lee, J Y, Uemura, H, De Porre, P, Smith, A A, Zhang, K, Lopez-Gitlitz, A, Smith, M R
Publicado 2019

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

por Gillessen, S., Omlin, A., Attard, G., de Bono, J. S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P. S., Sartor, O., Smith, M. R., Soule, H. R., Akaza, H., Beer, T. M., Beltran, H., Chinnaiyan, A. M., Daugaard, G., Davis, I. D., De Santis, M., Drake, C. G., Eeles, R. A., Fanti, S., Gleave, M. E., Heidenreich, A., Hussain, M., James, N. D., Lecouvet, F. E., Logothetis, C. J., Mastris, K., Nilsson, S., Oh, W. K., Olmos, D., Padhani, A. R., Parker, C., Rubin, M. A., Schalken, J. A., Scher, H. I., Sella, A., Shore, N. D., Small, E. J., Sternberg, C. N., Suzuki, H., Sweeney, C. J., Tannock, I. F., Tombal, B.
Publicado 2015